Reduction of gastric hyperemia by glypressin and vasopressin administration in cirrhotic patients with portal hypertensive gastropathy.
Gastric mucosal perfusion is increased in portal-hypertensive gastropathy, and this may contribute to gastric bleeding from these lesions. Therefore drugs reducing gastric mucosal perfusion may be beneficial in the treatment of overt bleeding from portal-hypertensive gastropathy. In this study gastric mucosal perfusion was assessed in 28 cirrhotic patients with portal-hypertensive gastropathy under basal conditions and after double-blind intravenous administration of vasopressin (0.4 U/min), glypressin (2-mg injection) or placebo, with laser-Doppler flowmetry and reflectance spectrophotometry. Vasopressin and glypressin induced a significant increase in blood pressure and a decrease in heart rate. These effects were more pronounced in the vasopressin group. Both vasopressin and glypressin induced a sustained and similar reduction in gastric mucosal perfusion as assessed by laser-Doppler flowmetry (-36% +/- 8% and -34% +/- 6%, respectively; p < 0.05 with respect to basal values and with respect to the control group), whereas placebo had no effect. Both drugs significantly reduced the oxygen content of the gastric mucosa; however, the impairment in mucosal oxygenation was greater (p < 0.05) in the vasopressin group (-17% +/- 3%) than in the glypressin group (-6% +/- 0.1%). We conclude that the increased gastric perfusion in cirrhotic patients with portal-hypertensive gastropathy may be reduced by either vasopressin or glypressin. These findings support the use of these drugs in clinical trials treating bleeding portal-hypertensive gastropathy. The lower reduction in gastric mucosal oxygen content observed with glypressin could decrease the incidence of ischemic adverse events associated with the use of vasopressin.
Panés
J
J
Gastroenterology Department, Hospital Clínic, Barcelona, Spain.
Piqué
J M
JM
Bordas
J M
JM
Llach
J
J
Bosch
J
J
Terés
J
J
Rodés
J
J
D004311:Double-Blind Method; D005260:Female; D005753:Gastric Mucosa / Q000098:blood supply* / Q000378:metabolism; D006471:Gastrointestinal Hemorrhage / Q000188:drug therapy / Q000209:etiology; D005773:Gastroscopy; D006801:Humans; D006940:Hyperemia / Q000188:drug therapy*; D006975:Hypertension, Portal / Q000150:complications*; D017078:Laser-Doppler Flowmetry; D008103:Liver Cirrhosis / Q000150:complications*; D008236:Lypressin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010100:Oxygen / Q000378:metabolism; D012039:Regional Blood Flow / Q000187:drug effects; D013053:Spectrophotometry / Q000379:methods; D013272:Stomach Diseases / Q000188:drug therapy / Q000209:etiology*; D000077585:Terlipressin; D014667:Vasopressins / Q000627:therapeutic use*
D014667:Vasopressins; D008236:Lypressin; D000077585:Terlipressin; D010100:Oxygen